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Abstract
Virtual screening is used in biomedical research to predict the binding affinity of a large set of small organic
molecules to protein receptor targets. This report shows the development and evaluation of a novel yet
straightforward attempt to improve this ranking in receptor-based molecular docking using a receptor-decoy
strategy. This strategy includes defining a decoy binding site on the receptor and adjusting the ranking of the true
binding-site virtual screen based on the decoy-site screen. The results show that by docking against a receptor-
decoy site with Autodock Vina, improved Receiver Operator Characteristic Enrichment (ROCE) was achieved for 5
out of fifteen receptor targets investigated, when up to 15 % of a decoy site rank list was considered. No improved
enrichment was seen for 7 targets, while for 3 targets the ROCE was reduced. The extent to which this strategy can
effectively improve ligand prediction is dependent on the target receptor investigated.
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Protein 90; InhA, Enoyl ACP Reductase; MR, Mineralocorticoid Receptor; parp, Poly (ADP-ribose) Polymerase;
Pparg, Peroxisome Proliferator Activated Receptor Gamma; PR, Progesterone Receptor; ROCE, Receiver Operator
Characteristic Enrichment; RXRa, Retinoic X Receptor Alpha; VEGFr2, Vascular Endothelial Growth Factor Receptor Kinase
Background
Virtual screening is a widely used technique in the field
of medicinal chemistry to identify lead compounds from
a diverse library that can bind to a receptor. The recep-
tor based virtual screening approach involves a process
called molecular docking which employs an algorithm
that docks each molecule from a library into the binding
site in order to predict a binding energy or a binding
score [1]. In recent years, a number of successful virtual
screening based studies have been conducted as de-
scribed for example in the recent review by Lavecchia
et al. [2]. Although docking provides an efficient and
cost effective way to assess interactions between mole-
cules such as proteins and ligands on a large-scale, the
accuracy, as defined by the ability to predict strong bind-
ing ligands, is limited. This is largely due to the limita-
tion of scoring functions used in the software to
calculate binding energies, and therefore their ability to
identify true positives from a database composed of
known ligands and decoys that is typically used in evalu-
ations of virtual screening [3, 4]. The accuracy of the
screening method can be assessed quantitatively
through calculation of the robust metric known as Re-
ceiver Operator Characteristic Enrichment (ROCE) [5].
An ROCE factor is obtained as the true positive rate di-
vided by the false positive rate, thus ROCE factors
much larger than 1.0 are desirable to establish that the
docking algorithm can distinguish active compounds
from decoys.
Several software for molecular docking are available [6]
and have been evaluated [7, 8]. Furthermore, methods to
increase the accuracy of virtual screening have been sug-
gested, for example considering receptor flexibility to re-
duce the numbers of false positive molecules [9], consensus
docking to predict correct binding pose [10], and a consen-
sus virtual screening method that combined the rank lists
of ligands from different algorithms [11]. However, these
improved methods can still result in a low number of cor-
rect predictions for some receptors [11]. In the work
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described here the novel strategy of using receptor decoy
sites was developed and evaluated for the first time together
with the docking software AutoDock Vina [12]. This in-
volved performing virtual screening against a non-binding
(receptor-decoy) site on the same protein target, and devel-
oping a way to re-rank the screening results, thus enabling
a comparison of ROCE factors before and after the applica-
tion of receptor-decoy screening in order to evaluate the
novel strategy.
Methods
Ligand and decoy sets for fifteen target proteins were
downloaded from the Database of Useful Decoys [3].
The complexes were selected from several different pro-
tein categories in the database such as hormone recep-
tors, kinases, proteases and other enzymes to represent a
wide range of targets, including 10 targets which had
previously been evaluated [11]. Virtual screening for all
fifteen targets was performed using Autodock Vina
version 1.1.1 with the default parameters [12]. The
FTMap binding site prediction server [13] was used
to help define the decoy site for docking. The
FTMap server identifies binding hot-spots by compu-
tational solvent mapping whereby 16 different mo-
lecular probes are docked onto the protein surface to
locate favorable binding regions [13]. The decoy site
was chosen based on the following criteria: 1) con-
tains no binding hotspot predicted by FTMap, 2) it
appears structurally different to the actual binding
site and 3) it does not form an obvious binding cav-
ity but is at a flat region on the exterior surface of
the protein. The search space for docking was de-
fined via a grid box manually specified with Auto-
dock Tools [14] around the binding or decoy site. A
grid spacing of 0.375 Å was used to determine the
box dimensions. The box dimensions remained the
same for binding site and decoy site docking. Ad-
justed rank lists were generated from the binding site
list by considering molecules that were in the top
10 %, 15 %, 20 %, 30 % and 50 % of the decoy site
list, and adjusting the rank of the binding site list
using the following formula:
Adjusted rank ¼ Binding site rank−Decoy site rankð Þ
þTotal no:of ligands in list
The fraction of decoy-site docking results was var-
ied in order to find a cut-off where maximum enrich-
ment is achieved. The numbers of active ligands in
the database were then used to calculate the ROC
Enrichment (ROCE) factors at 1 % and 2 % of the
number of molecules. The ROCEx% was calculated as
the fraction of true positives divided by the fraction
of false positives at x% of the ligand/decoy database
according to the equation:
ROCEx% ¼ f actives
1−
Ndecoys−Ninactivesð Þ
Ndecoys
Where factives = (number of actives at x%) / (number of
all actives),
Ndecoys = the total number of inactive decoys,
Ninactives = the number of decoys chosen at x% of the
ligand/decoy database.
Binding site and decoy sites were analysed post-
docking with the KVFinder Cavity Detection PyMol Plu-
gin [15] to provide a quantitative description of the two
sites. The software enables comparison and characterisa-
tion of protein binding sites by the number, area and
volume of cavities in a specified search space. The de-
fault parameters were used for all fifteen targets which
included a probe in size of 1.4 Å, probe out size of 4.0 Å
and a step size of 0.6 Å. The minimum cavity volume
was set at 5.0 Å. The binding site search space was set
around the position of the actual ligand molecule ob-
tained from the Protein Data Bank, and the decoy site
search space was set using a docked molecule from the
decoy site screening.
Results and discussion
High predicted binding affinities between a ligand and a
receptor may not always correspond with the best bind-
ing molecules for the target site investigated [6, 16]. In
virtual screening this is reflected by low enrichment fac-
tors which indicate that many of the highest ranked
molecules may be false positive predictions [5]. In this
study, the level of Receiver Operator Characteristic En-
richment (ROCE) was determined at fractions of 1 %
and 2 % of the dataset of ligand/decoy molecules ob-
tained from the Database of useful Decoys [3]. Docking
against a non-binding ‘decoy’ site on the same receptor
(Fig. 1) was carried out using the software Autodock
Vina that lead to a ranking of molecules different from
the ranking for the true binding site. The predicted
binding energies among top molecules for the decoy site
were less negative than for binding sites, indicating a
lower degree of binding to the decoy site. The ranking
for the true binding site was adjusted by considering a
varied fraction of the rank list produced from the decoy
site from 0 % (no correction) to 50 % (Tables 1 and 2).
The results show a considerable variation between the
fifteen targets investigated confirming the general consen-
sus that virtual screening accuracy is highly dependent on
the target (Tables 1 and 2). Overall, the majority of targets
did not show any improvement in enrichment at the top
1 % or 2 % of the list after applying the receptor decoy
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method. Five targets (Comt, Ache, CDK2, HIVrt and
Pparg) show improved ROCE factors compared to those
obtained in the previous study [11], (see footnotes in Ta-
bles 1 and 2) when considering at least the top 15 % of the
decoy site list. Beyond 15 % the enrichment for all targets
(except HIVrt and Parp) either remained constant or
dropped to a lower value.
The rationale behind the receptor decoy strategy was
that the number of false positive binders could be re-
duced by determining molecules, which have a tendency
to bind non-specifically to molecular surfaces that are
different to the binding site. As a result a higher number
of active ligands would remain after adjusting the rank
list for the true binding site with the rank list for the
decoy site. However, the results show that this approach
is unlikely to help in the identification and selection of
molecules for experimental testing as a higher number
of true positives were recalled for only 5 out of 15 tar-
gets. The extent of enrichment achieved for the top 1 %
and 2 % differed for all targets due to properties that de-
termine the binding interactions between amino acid
residues of the target and the ligand-decoy dataset used
for docking. The optimum cut-off for maximum enrich-
ment at the top 1 % of a binding site list was obtained
when considering 15 % of the decoy list (Table 1), and
10 % for the top 2 % of the binding site list (Table 2).
This shows that the ranking of molecules with regards
Table 1 ROCE at 1 % of the binding site list considering top x%
of the decoy site list
Top % of decoy site list
Target 0 10 15 20 30 50
Comt 33.4a 39.0 39.0 39.0 39.0 39.0
AchE 1.0a 1.0 3.0 3.0 2.0 3.03
CDK2 14.3a 23.6 29.7 23.6 29.7 14.3
HIVrt 9.4a 13.1 13.1 9.0 13.1 18.0
Pparg 58.0a 99.0 84.0 84.0 84.0 84.0
FGFR1 0.0 0.0 0.9 0.9 0.9 0.9
InhA 14.6 5.3 5.3 5.3 2.5 0.0
PR 0.0 0.0 0.0 0.0 0.0 4.0
RXRa 212.4 212.4 212.4 88.5 47.2 88.5
VEGFr2 10.2 2.9 2.9 2.9 1.4 1.4
MR 178.3 178.3 71.3 71.3 71.3 71.3
Hsp90 0.0 0.0 0.0 0.0 0.0 0.0
AmpC 0.0 0.0 0.0 0.0 0.0 0.0
Trypsin 5.0 5.0 5.0 5.0 5.0 5.0
Parp 7.1 7.1 7.1 7.1 7.1 11.9
aResults taken from ref [11]
Table 2 ROCE at 2 % of the binding site list considering top x%
of the decoy site list
Top % of decoy site list
Target 0 10 15 20 30 50
Comt 10.4a 11.2 11.2 11.2 11.2 11.2
AchE 1.5a 2.0 2.0 1.5 2.0 1.5
CDK2 13.3a 15.7 15.7 15.7 11.9 5.8
HIVrt 8.8a 9.0 9.0 7.2 7.2 11.0
Pparg 35.8a 58.0 54.0 58.0 50.0 44.0
FGFR1 0.6 0.4 0.4 0.4 0.4 0.4
InhA 12.4 3.1 3.1 2.5 1.2 0.0
PR 0.0 0.0 0.0 0.0 1.9 4.0
RXRa 70.8 97.4 70.8 40.5 17.7 23.6
VEGFr2 5.3 1.4 2.1 2.1 2.9 1.4
MR 62.4 42.8 29.7 20.4 20.4 3.6
Hsp90 0.0 0.0 0.0 0.0 0.0 4.5
AmpC 0.0 0.0 0.0 0.0 0.0 0.0
Trypsin 5.0 5.0 5.0 5.0 5.0 5.0
Parp 5.1 3.2 7.1 7.1 7.1 9.4
aResults taken from ref [11]
Fig. 1 a Acetycholine esterase (Ache) receptor with binding site
shown in red and decoy site in blue. b Detailed view of Ache
binding site. c Detailed view of Ache decoy site
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to binding to the decoy sites is meaningless for lower
ranks.
The largest improvement in enrichment was achieved
with the targets CDK2 and Pparg. For the targets PR,
Hsp90 and ampC the ROCE at 1 % and 2 % remained at
zero until considering at least 30 % of molecules in the
decoy list, indicating that true and false ligands cannot
be distinguished by the Autodock Vina docking algo-
rithm. Cavity analyses of the binding site and decoy site
(Table 3) using the software KVFinder [15] shows that
the total number, volume and area of the cavities found
in the decoy site were smaller in comparison to the
binding site for all targets except HIVrt and trypsin. This
confirms that the shapes of the 2 sites are very different,
although this did not prevent false positive molecules
binding with high affinity.
The targets Inha, MR and VEGFr2 show a significant
decrease in ROCE indicating this strategy makes the re-
trieval of active ligands in the top ranks worse for these
targets. The actual binding site for VEGFr2 appears to
be non-specific, open and flat, therefore binds molecules
which also bind easily to the decoy site, resulting in a
high proportion of active molecules at the top of the
decoy list. However, the Inha binding site is a small,
deep pocket with a total cavity area of 838.4 Å2 which
appears not to be easily surface accessible, so it is ex-
pected that this receptor only binds ligands which are
complementary in shape. Although, this was not seen as
a higher number of active ligands were found in the top
1 % of the decoy site list compared to the binding site
list. Thus, when the re-ranking formula to generate the
adjusted list is applied, the binding site list is re-ordered
such that the active ligands do not appear in the top po-
sitions. This highlights the shortcoming, if applying this
strategy to a virtual screening experiment where active
molecules are not known, it cannot be guaranteed that
any improved prediction accuracy will result.
Conclusion
The novel development and evaluation of docking with
a decoy binding site shows that improved prediction of
active ligands could not be achieved in general. It should
be noted that the ligand/decoy dataset used for this
evaluation is especially challenging as decoys physico-
chemical similar to ligands were chosen [3]. The choice
of appropriate decoy binding sites is critical for the suc-
cess of this method. Choosing an obviously unfavorable
site, such as a flat molecular surface, reduces the docking
scores overall and thus the potential to discriminate be-
tween ligands and decoys, while on the other hand the
choice of an alternative binding cavity might cause a novel
mode of specific binding that does not help to eliminate
the false postives for the true binding site. The question,
how to define a decoy binding site, such that false positive
predictions for the real binding site are removed must re-
main open and is put forward to the academic commu-
nity. Further work addressing the re-ranking of predicted
ligands may also lead to improvements.
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Table 3 Cavity analysis of binding sites and decoy sites for all targets using KVFinder [15]
Binding site Cavities Decoy site cavities
Receptor Number Total Volume (Å3) Total Area (Å2) Number Total Volume (Å3) Total Area (Å2)
Comt 1 29.8 45.7 1 12.3 20.3
AchE 3 249.3 333.8 2 85.5 124.9
CDK2 4 134.0 178.3 1 10.6 15.8
HIVrt 5 92.1 138.7 1 241.3 240.1
Pparg 2 394.4 414.8 1 8.6 14.4
FGFR1 2 49.0 70.2 1 21.0 30.6
InhA 2 1119.7 834.8 1 6.0 10.1
PR 2 21.4 35.0 1 18.1 28.4
RXRa 1 57.5 72.0 1 21.0 30.2
Vegfr2 5 129.3 193.0 4 117.4 168.0
MR 2 54.4 78.1 1 23.5 35.6
Hsp90 4 166.8 233.7 2 30.0 46.1
ampC 3 100.8 121.3 1 5.8 9.7
trypsin 1 9.7 14.8 3 79.9 121.8
Parp 1 538.3 482.4 1 9.9 16.6
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